Dawn is a highly experienced health economic modeler with over 50 UK Health Technology Assessment submissions. She has worked across more than 30 countries globally and is a member of NICE’s interventional procedures advisory committee and the R for HTA group. Dawn is particularly focused on oncology modelling, immune-oncology, and flexible survival modelling. She also provides training on NICE processes and regularly represents clients at Committee meetings.
Dawn holds a Master’s in Mathematics (MMath, First Class) and a Master’s in Health Economics and Decision Modelling with distinction from ScHARR.
Represented manufacturers at approximately 30 HTA committee meetings, including key immune-oncology submissions such as the first immune-oncology submission to NICE (TA268).
Expert in flexible survival modelling
Specialises in oncology, immune-oncology, and the integration of external data in survival models.
Significant publication record
Widely published in fields related to health economics and HTA modelling.
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
